The PennZone

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased LifeStance Health Group, Inc. ("LifeStance" or the "Company") (NASDAQ: LFST) common stock pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with LifeStance's June 10, 2021 initial public stock offering (the "IPO"). LifeStance investors have until October 11, 2022 to file a lead plaintiff motion.

Investors suffering losses on their LifeStance investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On or about June 11, 2021, LifeStance conducted its IPO, issuing 46 million shares at $18 per share.

On August 11, 2021, LifeStance announced its financial results for second quarter 2021, which ended just days after the IPO. The Company reported a net loss of $70 million and also disclosed that its operating expenses had more than tripled during the second quarter. LifeStance stated that it had experienced a significant, negative "recent change in clinician retention levels."

On this news, the Company's stock price fell $10.16, or 46%, to close at $11.71 per share on August 12, 2021, thereby injuring investors.

More on The PennZone

• OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
• P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
• DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
• French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
• LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood

Then, on November 8, 2021, LifeStance released its third quarter 2021 financial results, disclosing that "[c]linician retention [had] stabilized to approximately 80% annualized in the third quarter," and that the Company was having to increase spending on "enhanced clinician engagement and continued support for workplace and work-life flexibility."

On this news, the Company's stock price fell $3.10, or 24%, to close at $9.73 per share on November 9, 2021, thereby injuring investors further.

Then, on March 10, 2022, LifeStance reported its fiscal 2021 results, stating that a recent study had shown that three quarters of mental health patients prefer in-person services and that through 2021, telehealth services trended downwards. Additionally, the Company stated that it would be reducing the number of brick and mortar facilities that it would be building in the immediate future in order to increase its profitability.

At the time the complaint was filed, LifeStance's common stock has traded as much as 73% below than the IPO price.

The complaint filed in this class action alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the number of virtual visits clients were undertaking utilizing LifeStance was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining the Company's out-patient/virtual revenue growth; (2) that the percentage of in-person visits clients were undertaking utilizing LifeStance was increasing as the COVID-19 lockdowns were being lifted, thereby causing the Company's operating expenses to increase substantially; (3) that LifeStance had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the Registration Statement and the Company had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

More on The PennZone

• Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
• STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
• Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
• New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
• Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow

If you purchased LifeStance common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

---

Show All News | Disclaimer | Report Violation